Immuneering Corp (IMRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$47.3M
Cash & Equivalents
$18.4M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$331M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | PHASE2 | Active Not Recruiting | 209 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-01 | 8-K | Immuneering Corp (IMRX) (CIK 0001790340) - 8-K | EDGAR |